Clinical trials: Lymphomas Non-Hodgkin's B-Cell
Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the effects, good and bad of a new drug called ixazomib (also called MLN9708), when it is given along with a common treatment combination, called Dose-Adjusted EPOCH-R (DA-EPOCH-R, for…
- Conditions
- Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, MYC Gene Mutation
- Trial name
- NCT02481310
- Testing
- Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- Northwestern University
B-Cell Lymphoma Originating in the CNS
The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma
The primary purpose of the study will be testing the dosing of temozolomide to find the target dose that a person can tolerate. The other part of the study will be determining how helpful it can be to CNS lymphoma patients by…
- Trial name
- DRBEAT (NCT01235793)
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center
Diffuse Large B-Cell Lymphoma (DLBCL)
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
A Single-Arm, Open-Label, Multicenter Phase II Trial of CRP Regimen (Chidamide, Rituximab, Polatuzumab Vedotin) in Treating Elderly Patients with Previously Untreated Double-Positive Diffuse Large B-Cell Lymphoma
- Trial name
- NCT07397832
- Testing
- Chidamide, Rituximab, Polatuzumab Vedotin
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-Hodgkin's B-cell Lymphoma
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
This is an active treatment, extended access study open solely to those subjects who have successfully completed the Core and Repeat Dosing portions of the MT-3724_NHL_001_US clinical study and who, in the investigator's…
- Trial name
- NCT02715843
- Testing
- MT-3724
- Where
- 3 sites in United States
- Sponsor
- Molecular Templates, Inc.
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134017
- Testing
- Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
This phase II study is designed to determine the clinical efficacy of PD-1 blockade, using the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475), administered as consolidation therapy after autologous stem cell transplant…
- Conditions
- Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
- Trial name
- NCT02362997
- Testing
- Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 82 people
- Sponsor
- Dana-Farber Cancer Institute
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
The purpose of this study is to test the safety of abexinostat at different doses to find out if it can work with ibrutinib to stop the cancer from growing.
- Trial name
- NCT03939182
- Testing
- Abexinostat, Ibrutinib
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
B-cell non-Hodgkin lymphoma (B-NHL) is the most common type of lymphoma. Although first-line R-CHOP can cure a proportion of patients, approximately 30%-40% relapse or become refractory (R/R).
- Trial name
- NCT07695896
- Testing
- Glofitamab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Yanyan Liu
Hematoma
A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
A Phase I/II Open-Label, Single-Arm, Multicenter Clinical Study of CM355 in Patients With R/R B-NHL
- Trial name
- NCT05210868
- Testing
- CM355
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
The goal of this clinical trial is to study the addition of Acalabrutinib to standard R-miniCHOP in older adults with DLBCL. The main question it aims to answer is whether progression free survival kann be prolonged with the…
- Trial name
- ARCHED (NCT05820841)
- Testing
- R-miniCHOP + Acalabrutinib, R-miniCHOP
- Where
- 17 sites in Germany
- Volunteers
- 330 people
- Sponsor
- Universität des Saarlandes
Renal Cell Carcinoma, Mantle-Cell Lymphoma
Safety Study of SGN-CD70A in Cancer Patients
This study will examine the safety profile of SGN-CD70A. The study will test increasing doses of SGN-CD70A given every 3 weeks (or an alternate dosing schedule up to every 6 weeks) to small groups of patients.
- Conditions
- Renal Cell Carcinoma, Mantle-Cell Lymphoma, Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3
- Trial name
- NCT02216890
- Testing
- SGN-CD70A
- Where
- 17 sites in United States
- Volunteers
- 38 people
- Sponsor
- Seagen Inc.
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
The purpose of this study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic properties of APG-2575 in patients with relapse or refractory chronic lymphocytic leukemia and non-hodgkin's lymphoma.
- Trial name
- NCT03913949
- Testing
- APG-2575
- Where
- 5 sites in China
- Volunteers
- 74 people
- Sponsor
- Ascentage Pharma Group Inc.
Small Cell Lung Cancer, Uveal Melanoma
A Study of PLX2853 in Advanced Malignancies.
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.
- Conditions
- Small Cell Lung Cancer, Uveal Melanoma, Ovarian Clear Cell Carcinoma, Non-Hodgkin Lymphoma
- Trial name
- NCT03297424
- Testing
- PLX2853
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Opna Bio LLC
Diffuse Large B Cell Lymphoma
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
The proposed study is a prospective, single-center and open-ended study in patients over the age of 70 with treatment-naive diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT05809180
- Testing
- Rituximab, Orelabrutinib, Pomalidomide
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia, Lymphoma
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor cells.
- Trial name
- NCT00019838
- Testing
- 7-hydroxystaurosporine, fludarabine phosphate
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Myeloma
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Patients have a type of cancer called NHL, Multiple Myeloma (MM) or CLL that has come back or has not gone away after treatment.
- Conditions
- Lymphoma, Myeloma, Leukemia
- Trial name
- CHARKALL (NCT00881920)
- Testing
- Kappa CD28 T cells
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Baylor College of Medicine
Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma
Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy
This study evaluates the addition of Atezolizumab to current therapy of Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) that are not candidates for…
- Conditions
- Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- ARGO (NCT03422523)
- Testing
- Atezolizumab, Rituximab, Gemcitabine 1000 mg
- Where
- United Kingdom
- Volunteers
- 53 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma
RATIONALE: Biological therapies, such as a dendritic cell vaccine made with a patient's cancer cells, may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00937183
- Testing
- autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine, autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine, autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine
- Where
- Poland
- Volunteers
- 12 people
- Sponsor
- Jan Walewski
Non-Hodgkin's Lymphoma
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
The purpose of this study is to test the safety of delivering the patients' own immune cells, called T cells, after the high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT).
- Trial name
- NCT01840566
- Testing
- Carmustine, Etoposide, Cytarabine
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B-Cell Lymphoma., Primary Mediastinal B-Cell Lymphoma
R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas
The purpose of this study is to show if addition of Rituximab to intensive induction (MegaCHOP/ESHAP) and high-dose consolidation (BEAM) improves progression-free and overall survival in patients younger than 65 years with…
- Conditions
- Diffuse Large B-Cell Lymphoma., Primary Mediastinal B-Cell Lymphoma, Follicular Lymphoma Grade III
- Trial name
- R-MCEB (NCT00558220)
- Testing
- immunotherapy, Induction treatment part 1, Induction treatment part 2 with PBPC collection
- Where
- 8 sites in Czechia
- Volunteers
- 106 people
- Sponsor
- Czech Lymphoma Study Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.